In the first half of 2020, HAEMATO AG achieved an EBITDA of EUR 2,066 thousand. Sales amounted to EUR 115.8 million.

In the first six months of the financial year 2020, HAEMATO AG, Berlin (ISIN: DE0006190705) achieved an IFRS group sales of EUR 115.8 million (previous year: EUR 94.0 million). This corresponds to an increase in sales of almost 23.19 % compared to the same period of the previous year. The result from ordinary business activities (EBITDA) of EUR 2,066 thousand (previous year: EUR 1,675 thousand) was also increased by approx. 23 % compared to the same period of the previous year.

The operating result (EBIT) of EUR 1,230 thousand (previous year: EUR 708 thousand) increased significantly by 73.82 % compared to the same period in the previous year. The non-cash depreciation of EUR -3,403 thousand on the fair value of the financial assets led to a net loss of EUR 2,820 thousand as of June 30, 2020.

Despite the massive restrictions caused by the Covid-19 pandemic, the Ordinary General Meeting of HAEMATO AG took place in Berlin on July 21, 2020. It was held as a face-to-face event in compliance with all the relevant hygiene measures. The resolutions proposed by the Executive Board and the Supervisory Board met with the approval of more than 99 % of the shareholders present.

The interim report is available for download on our corporate website at
https://haemato.ag/en/investor-relations/publications.

 

About HAEMATO:

HAEMATO AG, founded in 1993, is a pharmaceutical company. The business specialises on the growing markets of high-priced specialty pharmaceuticals. The main focus is on therapies for cancer, HIV and other chronic diseases.

HAEMATO AG is listed in the Basic Board (Open Market) of the Frankfurt Stock Exchange. Key figures on the HAEMATO AG share:
Subscribed capital: EUR 22,867,154
Listed class of shares: bearer ordinary shares
ISIN: DE000619070
WKN: 619070
Stock exchange code: HAE